Condition: Ovarian Cancer · Fallopian Tube Cancer · Sponsor: M.D. Anderson Cancer Center
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
This description comes directly from the study's public registry record.
Roni Wilke, MD · (713) 822-4502 · rnitecki@mdanderson.org
Always discuss trial participation with your own doctor first.
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| WU St Louis | St Louis, Missouri, United States | Recruiting |
| Mount Sinai Health System | New York, New York, United States | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
| Lyndon Baines Johnson General | Houston, Texas, United States | Recruiting |
| M D Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| University of Washington | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05287451